A meta-analysis has been performed including nineteen double blind, placebo controlled studies with piracetam in patients suffering from dementia or cognitive impairment in the elderly. These studies had as common outcome measure a clinical global impression of change, a measure of clinically meaningful improvement. The meta-analysis of this global outcome followed the methodology set forward by the Cochrane Collaboration. This article describes the studies, the patient populations and the methods of data extraction. The results of the meta-analysis demonstrate a difference between those individuals treated with piracetam and those given placebo, both as significant odds ratio and as a favourable number needed to treat. While there may be problems in meta-analyses and the interpretation of the statistical results, the results of this analysis provide compelling evidence for the global efficacy of piracetam in a diverse group of older subjects with cognitive impairment.

Keywords:
Piracetam, Cognition disorders, Meta-analysis, Randomised clinical trials
1.
Flicker L, Grimley J: The efficacy of piracetam in patients with dementia or cognitive impairment (Cochrane Review); in The Chochrane Library, Issue 1. Oxford, Update Software, 1997.
2.
Gotzsche PC: Why we need a broad perspective on meta-analysis. Editorial. BMJ 2000;321:585–586.
3.
Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s Disease. Am J Psychiatry 1982;141:1356–1364.
4.
Gottfries CG, Brane G, Steen G: A new rating scale for dementia syndromes. Gerontology 1982;28(suppl 2):20–31.
5.
Guy W (ed): ECDEU assessment manual for psychopharmacology, revised. Rockville, MD; US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH. Psychopharmacology Research Branch 1976:218–222.
6.
Leber P: Guidelines for the clinical evaluation of anti-dementia drugs. Letter to the Warner-Lambert Co., November 8, 1991; cited in Knopman DS, Knapp MJ, Gracon SJ, Davis CS: The Clinician Interview-Based Impression (CIBI): A clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994;44:2315–2321.
7.
Leber P: Discussion; in Schneider LS, Olin JT: Clinical Global Impression of Change. Clinical Global Impression in Alzheimer’s Clinical Trials. Int Psychogeriatr 1996;8:277–290.
8.
Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T: Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):8–18.
9.
Note for Guidance on Medicinal Products in the Treatment of Alzheimer’s Disease. CPMP/EWP/553/95, 1997.
10.
Lesaffre E, Pledger GW: A note on the number needed to treat. Control Clin Trials 1999;20:439–447.
11.
McLendon BM, Doraiswamy PM: Defining meaningful change in Alzheimer’s Disease trials. J Geriatr Psychiatry Neurol 1999;12:39–48.
12.
Anonymous: Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR) Exelon. Rev1, CPMP/243/98.
13.
Olin J, Schneider L: Galantamine for Alzheimer’s Disease (Cochrane Review); in: The Chochrane Library, issue 1, 2001. Oxford, Update Software.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.